Merck reports fiscal Q1 2026 results: revenue $16.29B, up 5% from a year earlier

Merck filed a Form 8-K with the SEC on Apr 30, 2026, 6:53 AM ET, reporting an event dated Apr 30, 2026. It covers Item 2.02 (Results of Operations and Financial Condition); Item 9.01 (Financial Statements and Exhibits). The results cover fiscal Q1 2026 (quarter ended Mar 31, 2026); figures below are from the company's XBRL financial data filed with the SEC.

• Revenue: $16.29B (+4.9% from $15.53B a year earlier)
• Net income: −$4.24B (vs $5.08B a year earlier)
• Diluted EPS: $-1.72 (vs $2.01 a year earlier)
• Form 8-K accepted by EDGAR Apr 30, 2026, 6:53 AM ET
• Accession number 0001104659-26-052081

SEC filing 8-K · accession 0001104659-26-052081 · sec.gov ↗